Vancouver Coastal Health Eye Care Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ramdin, Namita
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Active, not recruiting
4
446
Europe, Canada, US, RoW
Faricimab
McMaster University, Hoffmann-La Roche
Diabetic Macular Edema
12/26
12/26
LIDS, NCT05276063: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Active, not recruiting
2/3
90
Europe, Canada, US
Linsitinib, Placebo
Sling Therapeutics, Inc.
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
10/24
09/26
NCT05984927: NG101 AAV Gene Therapy in Subjects with Wet Age-Related Macular Degeneration

Recruiting
1/2
18
Canada, US
NG101 AAV gene therapy, NG101
Neuracle Genetics, Inc, ORA, Inc.
Age-Related Macular Degeneration
01/26
01/30
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ramdin, Namita
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Active, not recruiting
4
446
Europe, Canada, US, RoW
Faricimab
McMaster University, Hoffmann-La Roche
Diabetic Macular Edema
12/26
12/26
LIDS, NCT05276063: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Active, not recruiting
2/3
90
Europe, Canada, US
Linsitinib, Placebo
Sling Therapeutics, Inc.
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
10/24
09/26
NCT05984927: NG101 AAV Gene Therapy in Subjects with Wet Age-Related Macular Degeneration

Recruiting
1/2
18
Canada, US
NG101 AAV gene therapy, NG101
Neuracle Genetics, Inc, ORA, Inc.
Age-Related Macular Degeneration
01/26
01/30

Download Options